Ocular Therapeutix, Inc. OCUL
9.65
(0.17)
(1.73%)
as of 25 Sep
- Market cap
- $2.2B
- P/E
- 0.0×
Follow OCUL
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (72.99%) | (68.55%) | (54.85%) | (81.83%) |
+8 more TTM periods Free account |
|
| (53.70%) | (51.03%) | (42.01%) | (55.41%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(49.04%) | (42.93%) | (35.41%) | (70.40%) | |
Average Days of Receivables |
212.19 | 170.77 | 215.34 | 201.32 | |
Free Cash Flow per Share |
(1.13) | (1.07) | (1.16) | (1.08) | |
Free Cash Flow |
(255.10) | (240.81) | (216.76) | (199.31) | |
Capital Expenditures |
(16.86) | (14.61) | (11.88) | (9.24) | |
Piotroski F-Score |
3.00 | 3.00 | 4.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(20.00%) | (17.13%) | (14.01%) | (28.22%) | |
Accounts Receivable Turnover |
1.72 | 2.10 | 1.65 | 1.83 | |
Accounts Payable Turnover |
1.04 | 1.05 | 1.58 | 1.21 | |
Inventory Turnover |
1.95 | 1.90 | 1.99 | 2.11 | |
Average Days of Payables |
380.67 | 441.12 | 230.64 | 367.94 | |
Days of Inventory on Hand |
208.18 | 205.39 | 197.88 | 205.01 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
429.38% | 423.64% | 379.39% | 335.73% | |
Selling, General and Administrative Expense of Revenue |
260.78% | 239.03% | 227.71% | 202.78% | |
Share Based Compensation of Revenue |
102.36% | 92.84% | 83.12% | 69.95% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.78 | 0.77 | 0.76 | |
Depreciation/Fixed assets |
0.28 | 0.25 | 0.22 | 0.24 | |
Capex/Depreciation |
(3.09) | (3.16) | (2.75) | (2.30) | |
Revenue per Share |
0.23 | 0.23 | 0.28 | 0.30 | |
Operating CF per Share |
(1.06) | (1.01) | (1.09) | (1.03) | |
Capex per Share |
(0.07) | (0.07) | (0.06) | (0.05) | |
Capex to Sales |
0.32 | 0.28 | 0.23 | 0.17 | |
Net Profit Margin |
(579.10%) | (558.24%) | (511.90%) | (447.57%) |
Columns are period end dates